Danish pharmaceutical giant Novo Nordisk on Tuesday released updated late-stage analysis data for its next-generation experimental obesity drug, CagriSema. The results showed that among approximately 2,300 obese or overweight adult women, the drug led to an average weight loss of 25%, outperforming its best-selling GLP-1 drug, Wegovy. CagriSema combines semaglutide (the active ingredient in Wegovy) with cagrilintide, another drug that targets the amylin pathway, and is expected to launch early next year. FactSet consensus estimates the drug's sales in the obesity treatment sector alone will reach $11.84 billion by 2028.